AMGN Jan 2025 320.000 put
| Previous Close | 57.50 |
| Open | 57.50 |
| Bid | 48.25 |
| Ask | 51.15 |
| Strike | 320.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 57.50 - 57.50 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 895 |
- Reuters
UPDATE 1-Amgen first-quarter profit dips 1%, revenue rises 22%
Amgen reported a slightly lower first-quarter profit on Thursday, citing higher operating and interest expense from its recent acquisition of rare disease drugmaker Horizon Therapeutics, partially offset by double-digit revenue growth. The biotechnology company's adjusted profit fell 1% to $3.96 per share, which still beat the average analyst estimate of $3.88 per share, according to LSEG data. The results were "essentially in-linish ... although not anything significant for the Street given that it is still early in the year," David Song, portfolio manager of the Tema Obesity & Cardiometabolic ETF said in an email.
Investor's Business DailyAmgen Beats First-Quarter Expectations, But Shares Slide As Investors Watch Obesity Space
Amgen stock dipped late Thursday despite beating first-quarter expectations. The company is running a midstage study of its obesity drug.
ReutersAmgen first-quarter profit dips 1%, revenue rises 22%
(Reuters) -Amgen reported a slightly lower first-quarter profit on Thursday, citing higher operating and interest expense from its recent acquisition of rare disease drugmaker Horizon Therapeutics, partially offset by double-digit revenue growth. The biotechnology company's adjusted profit fell 1% to $3.96 per share, which still beat the average analyst estimate of $3.88 per share, according to LSEG data. The results were "essentially in-linish ... although not anything significant for the Street given that it is still early in the year," David Song, portfolio manager of the Tema Obesity & Cardiometabolic ETF said in an email.
